Prognostic Variables in Male Breast Cancer

Clark, John L.; Nguyen, Phuong L.; Jaszcz, Waclaw B.; Niehans, Gloria A.; Jatoi, Aminah
May 2000
American Surgeon;May2000, Vol. 66 Issue 5, p502
Academic Journal
The prognostic role of ploidy status, S phase fraction, estrogen and progesterone receptor status, and the expression of p53 and erbB-2 protein in male breast carcinoma (MBC) remains controversial. The primary objective of this study was to determine which of the common prognostic factors for female breast cancer predict prognosis in MBC. A secondary objective was to assess the impact of comorbid illnesses on survival. A retrospective review of demographic data, surgical treatment, pathological staging, adjuvant treatment and follow-up was completed for 16 patients with MBC (1 intraductal and 15 invasive). Formalin-fixed, paraffin-embedded tissue was processed for ploidy, S phase fraction, and immunohistochemical detection of estrogen and progesterone receptors plus expression of p53 and erbB-2 protein. Six of 15 patients with infiltrating ductal carcinoma are currently alive without evidence of disease and a median survival of 61 months. Nine patients died after a median survival of 52 months, with 6 patients having no evidence of recurrent breast cancer. Two of 3 deaths secondary to advanced breast cancer occurred in patients who initially presented with T4 lesions and were staged IIIB. Two of 15 tumors were erbB-2 positive, whereas only 1 tested weakly positive for p53 protein. We observed that MBCs express erbB-2 and p53 proteins infrequently. Neither ploidy status, S phase fraction, nor erbB-2/p53 status provided any apparent improvement in establishing prognosis beyond routine pathological staging. Advanced TNM stage was associated with diminished survival. The majority of MBCs express estrogen and progesterone receptors. Survivals in MBC were reduced in association with comorbid medical conditions.


Related Articles

  • The long-term prognosis for breast cancer. Pinkowish, Mary Desmond // Patient Care;10/15/1994, Vol. 28 Issue 16, p118 

    Reports on the long-term prognosis of breast cancer. Discovery of the tumors; Survival rates.

  • Telomerase activity and survival of patients with node-positive breast cancer. Clark, Gary M.; Osborne, C. Kent; Levitt, Daneil; Wu, Fred; Nam W. Kim; Clark, G M; Osborne, C K; Levitt, D; Wu, F; Kim, N W // JNCI: Journal of the National Cancer Institute;12/17/97, Vol. 89 Issue 24, p1874 

    Background: Shortening of telomeres (specialized structures at the ends of chromosomes) beyond a certain length may signal a cell to stop dividing and to enter senescence. A ribonucleoprotein enzyme, telomerase, is a key component in maintaining telomere length. Because the majority...

  • Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Keyomarsi, Khandan; Tucker, Susan L.; Bedrosian, Isabelle // Nature Medicine;Feb2003, Vol. 9 Issue 2, p152 

    Focuses on cyclin E as a predictor of breast cancer outcome. Cell proliferation indices; Measures of proliferation and S-phase fraction; Variability regarding tumor grade and prognosis.

  • Long term prognosis of women with breast cancer in New Zealand: study of survival to 30 years. Hibberd, A.D.; Horwood, L.J.; Wells, J.E. // British Medical Journal (Clinical Research Edition);6/4/1983, Vol. 286 Issue 6380, p1777 

    Examines the long-term prognosis of women with breast cancer in New Zealand. Decline of excess mortality rate; Need for prospective study; Biases on the reported cause of death.

  • Racial differences in survival from breast cancer. Eley, J. William; Hill, Holly A. // JAMA: Journal of the American Medical Association;9/28/94, Vol. 272 Issue 12, p947 

    Examines the ability of recognized prognostic factors for breast cancer to account for survival rates of black and white patients. Characteristics of subject respondents included in study; Use of multivariable survival models to estimate hazard ratio; Risk of dying for blacks and whites.

  • Mammary cancers and pregnancy. Anderson, John Maxwell // British Medical Journal;4/28/1979, Vol. 1 Issue 6171, p1124 

    Focuses on the management and prognosis of mammary cancers during and after pregnancy and lactation. Need for an interdisciplinary consultation; Efficacy of postoperative radiotherapy when the risk of local implantation is high; Termination of pregnancy when stage III or IV tumors develops.

  • Tumour location within the breast: Does tumour site have prognostic ability? Rummel, Seth; Hueman, Matthew T.; Costantino, Nick; Shriver, Craig D.; Ellsworth, Rachel E. // Ecancermedicalscience;2015, Vol. 9 Issue 549-576, p1 

    Introduction: Tumour location within the breast varies with the highest frequency in the upper outer quadrant (UOQ) and lowest frequency in the lower inner quadrant (LIQ). Whether tumour location is prognostic is unclear. To determine whether tumour location is prognostic, associations between...

  • TAZ oncogene as a prognostic factor in breast cancer. Glapa, Aleksandra; Nijak, Aleksandra // Journal of Medical Science;2015, Vol. 84 Issue 2, p107 

    Breast cancer is the most frequently diagnosed cancer in females and one of the main causes of cancer related deaths. Breast cancer in the metastatic stage is related with poor prognosis. Metastasis is the process whereby cancer cells travel to and colonize distant sites through the lymphatic...

  • Researchers identify new genes that determine breast cancer prognosis.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p427 

    The article reports on the discovery of a new gene that will aid in assessing the prognosis of breast cancer by researchers at the Wake Forest Baptist Medical Center.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics